Publications by authors named "Rebecca M Mingo"

Unlabelled: The highly pathogenic severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) cause significant morbidity and morality. There is currently no approved therapeutic for highly pathogenic coronaviruses, even as MERS-CoV is spreading throughout the Middle East. We previously screened a library of FDA-approved drugs for inhibitors of coronavirus replication in which we identified Abelson (Abl) kinase inhibitors, including the anticancer drug imatinib, as inhibitors of both SARS-CoV and MERS-CoV in vitro Here we show that the anti-CoV activity of imatinib occurs at the early stages of infection, after internalization and endosomal trafficking, by inhibiting fusion of the virions at the endosomal membrane.

View Article and Find Full Text PDF
Article Synopsis
  • EBOV causes severe hemorrhagic fevers and is internalized through macropinocytosis before releasing its RNA genome into the cytoplasm after a notable delay compared to other viruses.
  • The delay in cytoplasmic entry for EBOV is linked to its requirement to reach Niemann-Pick C1 (NPC1)-positive endolysosomes, which is essential for effective fusion and release.
  • Interestingly, the SARS-CoV also experiences a similar lag in entry despite not needing NPC1, highlighting that both viruses require deeper endocytic trafficking to access areas with enhanced cathepsin L activity for successful infection.
View Article and Find Full Text PDF

In the final stages of the herpes simplex virus 1 (HSV-1) life cycle, a viral nucleocapsid buds into a vesicle of trans-Golgi network (TGN)/endosome origin, acquiring an envelope and an outer vesicular membrane. The virus-containing vesicle then traffics to the plasma membrane where it fuses, exposing a mature virion. Although the process of directed egress has been studied in polarized epithelial cell lines, less work has been done in nonpolarized cell types.

View Article and Find Full Text PDF